Targeting metabolic disturbance in the diabetic heart

Cardiovascular Diabetology

Volumn 14, Issue 1, 2015, Pages

  Fuentes Antrás, Jesús ^a   Picatoste, Belén ^a,b   Ramírez, Elisa ^a,b   Egido, Jesús ^a,b   Tuñón, José ^a   Lorenzo, Óscar ^a,b  

^a 28400 Madrid   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Advanced glycation end products; Diabetic cardiomyopathy; Dipeptidyl peptidase 4; Fatty acid translocase cluster of differentiation 36; Glucagon like protein 1; Metformin; Nod like receptor 3; Peroxisome proliferator activated receptor agonists; Statins; Toll like receptor 4

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TRANSPORTER 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIRAGLUTIDE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

DIABETIC CARDIOMYOPATHY; DIABETIC PATIENT; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HEART; HEART PERFORMANCE; HEART VENTRICLE HYPERTROPHY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; ANIMAL; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHIES; DRUG DELIVERY SYSTEM; METABOLIC DISEASES; METABOLISM; TRENDS;

ANIMALS; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHIES; DRUG DELIVERY SYSTEMS; HUMANS; METABOLIC DISEASES;

EID: 84924298451     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-015-0173-8     Document Type: Review

References (96)

1. Diabetes Atlas | International Diabetes Federation. [ http://www.idf.org/diabetesatlas ]
2. Bell DSH. Diabetic Cardiomyopathy. Diabetes Care. 2003;26:2949-51.
3. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care. 2001;24:5-10.
4. Kiencke S, Handschin R, von Dahlen R, Muser J, Brunner-Larocca HP, Schumann J, et al. Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcome. Eur J Heart Fail. 2010;12:951-7.
5. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57(4):660-71.
6. Manjarrez-Gutiérrez G, Hernández-Chávez V, Neri-Gómez T, Boyzo-Montes de Oca A, Mondragón-Herrera JA, Hernández-Rodríguez J. Anatomopathological findings during development of diabetic cardiomyopathy in rats. Cir Cir. 2014;82:11-9.
7. Phillips RA, Krakoff LR, Dunaif A, Finegood DT, Gorlin R, Shimabukuro S. Relation among left ventricular mass, insulin resistance, and blood pressure in nonobese subjects. J Clin Endocrinol Metab. 1998;83:4284-8.
8. Moore A, Shindikar A, Fomison-Nurse I, Riu F, Munasinghe PE, Ram TP, et al. Rapid onset of cardiomyopathy in STZ-induced female diabetic mice involves the downregulation of pro-survival Pim-1. Cardiovasc Diabetol. 2014;13:68.
9. Mazzone T. Intensive Glucose Lowering and Cardiovascular Disease Prevention in Diabetes Reconciling the Recent Clinical Trial Data. Circulation. 2010;122:2201-11.
10. Hamblin M, Friedman DB, Hill S, Caprioli RM, Smith HM, Hill MF. Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. J Mol Cell Cardiol. 2007;42:884-95.
11. Palomer X, Salvadó L, Barroso E, Vázquez-Carrera M. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. Int J Cardiol. 2013;168:3160-72.
12. Zhang S, Liu H, Amarsingh GV, Cheung CCH, Hogl S, Narayanan U, et al. Diabetic cardiomyopathy is associated with defective myocellular copper regulation and both defects are rectified by divalent copper chelation. Cardiovasc Diabetol. 2014;13:100.
13. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet. 1998;352:854-865.
14. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L et al. Comparative Safety and Effectiveness of Metformin in Patients with Diabetes and Heart Failure: Systematic Review of Observational Studies Involving 34000 Patients. Circ Heart Fail.2013;CIRCHEARTFAILURE.112.000162.
15. Verma S, McNeill JH. Metformin improves cardiac function in isolated streptozotocin-diabetic rat hearts. Am J Physiol. 1994;266(2 Pt 2):H714-9.
16. Da Silva D, Ausina P, Alencar EM, Coelho WS, Zancan P, Sola-Penna M. Metformin reverses hexokinase and phosphofructokinase downregulation and intracellular distribution in the heart of diabetic mice. IUBMB Life. 2012;64:766-74.
17. Xie Z, Lau K, Eby B, Lozano P, He C, Pennington B, et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes. 2011;60:1770-8.
18. Kim J, Wietecha TA, Dai D-F, Sullivan B, Sta Teresa A, Hudkins KL, et al. Metformin Prevents the Development of Cardiomyopathy and Cardiac Dysfunction in Diabetogenic Diet-fed BTBRob/+ Mice (Abstract). Circulation. 2012;126:A17997 [ http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A17997 ]
19. Forcheron F, Basset A, Abdallah P, Carmine PD, Gadot N, Beylot M. Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model - the Zucker diabetic rat. Cardiovasc Diabetol. 2009;8:16.
20. Picatoste B, Ramírez E, Caro-Vadillo A, Iborra C, Egido J, Tuñón J, et al. Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. PLoS One. 2013;8:e78330.
21. Rösen P, Wiernsperger NF. Metformin delays the manifestation of diabetes and vascular dysfunction in Goto-Kakizaki rats by reduction of mitochondrial oxidative stress. Diabetes Metab Res Rev. 2006;22:323-30.
22. Quentin T, Steinmetz M, Poppe A, Thoms S. Metformin differentially activates ER stress signaling pathways without inducing apoptosis. Dis Model Mech. 2012;5:259-69.
23. Mozaffari MS, Allo S, Schaffer SW. The effect of sulfonylurea therapy on defective calcium movement associated with diabetic cardiomyopathy. Can J Physiol Pharmacol. 1989;67:1431-6.
24. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-72.
25. Shida T, Nozawa T, Sobajima M, Ihori H, Matsuki A, Inoue H. Fluvastatin-induced reduction of oxidative stress ameliorates diabetic cardiomyopathy in association with improving coronary microvasculature. Heart Vessels. 2014;29(4):532-41.
26. Quidgley J, Cruz N, Crespo MJ. Atorvastatin improves systolic function, but does not prevent the development of dilated cardiomyopathy in streptozotocin-induced diabetic rats. Ther Adv Cardiovasc Dis. 2014;8(4):133-44.
27. Baraka A, AbdelGawad H. Targeting apoptosis in the heart of streptozotocin-induced diabetic rats. J Cardiovasc Pharmacol Ther. 2010;15:175-81.
28. Hemmeryckx B, Swinnen M, Gallacher DJ, Rong Lu H, Roger Lijnen H. Effect of sitagliptin treatment on metabolism and cardiac function in genetic diabetic mice. Eur J Pharmacol. 2014;723:175-80.
29. Hemmeryckx B, Hoylaerts MF, Gallacher DJ, Rong Lu H, Himmelreich U, D'hooge J, et al. Does rosiglitazone affect adiposity and cardiac function in genetic diabetic mice? Eur J Pharmacol. 2013;700:23-31.
30. Lenski M, Kazakov A, Marx N, Böhm M, Laufs U. Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J Mol Cell Cardiol. 2011;51:906-18.
31. Aasum E, Belke DD, Severson DL, Riemersma RA, Cooper M, Andreassen M, et al. Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol. 2002;283:H949-57.
32. Carley AN, Semeniuk LM, Shimoni Y, Aasum E, Larsen TS, Berger JP, et al. Treatment of type 2 diabetic db/db mice with a novel PPARgamma agonist improves cardiac metabolism but not contractile function. Am J Physiol Endocrinol Metab. 2004;286:E449-55.
33. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. Diabetes. 2002;51:1110-7.
34. Liu J, Liu Y, Chen L, Wang Y, Li J. Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress Pathway. J Diabetes Res. 2013;2013:630537.
35. Noyan-Ashraf MH, Shikatani EA, Schuiki I, Mukovozov I, Wu J, Li R-K, et al. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation. 2013;127:74-85.
36. Mells JE, Fu PP, Sharma S, Olson D, Cheng L, Handy JA, et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol - Gastrointest Liver Physiol. 2012;302:G225-35.
37. Luo B, Li B, Wang W, Liu X, Liu X, Xia Y, et al. Rosuvastatin Alleviates Diabetic Cardiomyopathy by Inhibiting NLRP3 Inflammasome and MAPK Pathways in a Type 2 Diabetes Rat Model. Cardiovasc Drugs Ther Spons Int Soc Cardiovasc Pharmacother. 2014;28(1):33-43.
38. Aasum E, Khalid AM, Gudbrandsen OA, How O-J, Berge RK, Larsen TS. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice. J Mol Cell Cardiol. 2008;44:201-9.
39. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-26.
40. Ravassa S, Barba J, Coma-Canella I, Huerta A, López B, González A, et al. The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2013;12:143.
41. Barylski M, Nikolic D, Banach M, Toth PP, Montalto G, Rizzo M. STATINS AND NEW-ONSET DIABETES. Curr Pharm Des. 2013.
42. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, et al. Effects of Torcetrapib in Patients at High Risk for Coronary Events. N Engl J Med. 2007;357:2109-22.
43. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-61.
44. Komajda M, McMurray JJV, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010;31:824-31.
45. Giles TD, Miller AB, Elkayam U, Bhattacharya M, Perez A. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail. 2008;14:445-52.
46. Semeniuk LM, Kryski AJ, Severson DL. Echocardiographic assessment of cardiac function in diabeticdb/db and transgenic db/db-hGLUT4 mice. Am J Physiol - Heart Circ Physiol. 2002;283:H976-82.
47. Chambers KT, Leone TC, Sambandam N, Kovacs A, Wagg CS, Lopaschuk GD, et al. Chronic Inhibition of Pyruvate Dehydrogenase in Heart Triggers an Adaptive Metabolic Response. J Biol Chem. 2011;286:11155-62.
48. Kajstura J, Fiordaliso F, Andreoli AM, Li B, Chimenti S, Medow MS, et al. IGF-1 Overexpression Inhibits the Development of Diabetic Cardiomyopathy and Angiotensin II-Mediated Oxidative Stress. Diabetes. 2001;50:1414-24.
49. Liu L, Trent CM, Fang X, Son N-H, Jiang H, Blaner WS et al. Cardiomyocyte specific loss of diacylglycerol acyl transferase 1 (DGAT1) reproduces the abnormalities in lipids found in severe heart failure. J Biol Chem. 2014.
50. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen Y-T, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006;317:1106-13.
51. Nagashima M, Watanabe T, Terasaki M, Tomoyasu M, Nohtomi K, Kim-Kaneyama J, et al. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia. 2011;54:2649-59.
52. Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis. 2013;226:305-14.
53. Witteles RM, Keu KV, Quon A, Tavana H, Fowler MB. Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy. J Card Fail. 2012;18:804-9.
54. Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010;3:195-201.
55. Ma H, Li S-Y, Xu P, Babcock SA, Dolence EK, Brownlee M, et al. Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy. J Cell Mol Med. 2009;13:1751-64.
56. Brouwers O, de Vos-Houben JMJ, Niessen PMG, Miyata T, van Nieuwenhoven F, Janssen BJA, et al. Mild oxidative damage in the diabetic rat heart is attenuated by glyoxalase-1 overexpression. Int J Mol Sci. 2013;14:15724-39.
57. Hu Y, Belke D, Suarez J, Swanson E, Clark R, Hoshijima M, et al. Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart. Circ Res. 2005;96:1006-13.
58. Son N-H, Yu S, Tuinei J, Arai K, Hamai H, Homma S, et al. PPARγ-induced cardiolipotoxicity in mice is ameliorated by PPARα deficiency despite increases in fatty acid oxidation. J Clin Invest. 2010;120:3443-54.
59. Burkart EM, Sambandam N, Han X, Gross RW, Courtois M, Gierasch CM, et al. Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest. 2007;117:3930-9.
60. Yang J, Sambandam N, Han X, Gross RW, Courtois M, Kovacs A, et al. CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res. 2007;100:1208-17.
61. Duncan JG, Bharadwaj KG, Fong JL, Mitra R, Sambandam N, Courtois MR, et al. Rescue of cardiomyopathy in peroxisome proliferator-activated receptor-alpha transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator-activated receptor-alpha activators. Circulation. 2010;121:426-35.
62. Kuramoto K, Sakai F, Yoshinori N, Nakamura TY, Wakabayashi S, Kojidani T, et al. Deficiency of a lipid droplet protein, Perilipin 5, suppresses myocardial lipid accumulation, thereby preventing type 1 diabetes-induced heart malfunction. Mol Cell Biol. 2014;34(14):2721-31.
63. Pulinilkunnil T, Kienesberger PC, Nagendran J, Waller TJ, Young ME, Kershaw EE, et al. Myocardial Adipose Triglyceride Lipase Overexpression Protects Diabetic Mice From the Development of Lipotoxic Cardiomyopathy. Diabetes. 2013;62:1464-77.
64. Pulinilkunnil T, Kienesberger PC, Nagendran J, Sharma N, Young ME, Dyck JRB. Cardiac-specific adipose triglyceride lipase overexpression protects from cardiac steatosis and dilated cardiomyopathy following diet-induced obesity. Int J Obes. 2014;38(2):205-15.
65. Ueno M, Suzuki J, Zenimaru Y, Takahashi S, Koizumi T, Noriki S, et al. Cardiac overexpression of hormone-sensitive lipase inhibits myocardial steatosis and fibrosis in streptozotocin diabetic mice. Am J Physiol Endocrinol Metab. 2008;294:E1109-18.
66. Suzuki H, Kayama Y, Sakamoto M, Iuchi H, Shimizu I, Yoshino T et al. Arachidonate 12/15-Lipoxygenase-Induced Inflammation and Oxidative Stress Are Involved in the Development of Diabetic Cardiomyopathy. Diabetes. 2014.Sep 3.
67. Matsui H, Yokoyama T, Sekiguchi K, Iijima D, Sunaga H, Maniwa M, et al. Stearoyl-CoA desaturase-1 (SCD1) augments saturated fatty acid-induced lipid accumulation and inhibits apoptosis in cardiac myocytes. PLoS One. 2012;7:e33283.
68. Liu L, Yu S, Khan RS, Homma S, Schulze PC, Blaner WS, et al. Diacylglycerol acyl transferase 1 overexpression detoxifies cardiac lipids in PPARγ transgenic mice. J Lipid Res. 2012;53:1482-92.
69. Liu L, Shi X, Bharadwaj KG, Ikeda S, Yamashita H, Yagyu H, et al. DGAT1 Expression Increases Heart Triglyceride Content but Ameliorates Lipotoxicity. J Biol Chem. 2009;284:36312-23.
70. Chou I-P, Chiu Y-P, Ding S-T, Liu B-H, Lin YY, Chen C-Y. Adiponectin receptor 1 overexpression reduces lipid accumulation and hypertrophy in the heart of diet-induced obese mice - possible involvement of oxidative stress and autophagy. Endocr Res. 2014;39(4):173-9.
71. Park M, Wu D, Park T, Choi C, Li R-K, Cheng KKY, et al. APPL1 transgenic mice are protected from high-fat diet-induced cardiac dysfunction. Am J Physiol Endocrinol Metab. 2013;305:E795-804.
72. Yokoyama M, Yagyu H, Hu Y, Seo T, Hirata K, Homma S, et al. Apolipoprotein B Production Reduces Lipotoxic Cardiomyopathy studies in heart-specific lipoprotein lipase transgenic mouse. J Biol Chem. 2004;279:4204-11.
73. Haitao Z, Zhongwei L, Kunlun C, Xin D, Chuan Q, Dengfeng G. ASSA13-06-6 Prevention of Cardiac Remodelling by Gene Silencing of Toll-Like Receptor-4 in Mice with Diabetic Cardiomyopathy. Heart. 2013;99 Suppl 1:A35-A35.
74. Zhang Y, Peng T, Zhu H, Zheng X, Zhang X, Jiang N, et al. Prevention of hyperglycemia-induced myocardial apoptosis by gene silencing of Toll-like receptor-4. J Transl Med. 2010;8:133.
75. Dong B, Qi D, Yang L, Huang Y, Xiao X, Tai N, et al. TLR4 regulates cardiac lipid accumulation and diabetic heart disease in the nonobese diabetic mouse model of type 1 diabetes. Am J Physiol Heart Circ Physiol. 2012;303:H732-42.
76. Wang W-K, Wang B, Lu Q-H, Zhang W, Qin W-D, Liu X-J, et al. Inhibition of high-mobility group box 1 improves myocardial fibrosis and dysfunction in diabetic cardiomyopathy. Int J Cardiol. 2014;172(1):202-12.
77. Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376:431-9.
78. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, de Groof RC. The Effect of Alagebrium Chloride (ALT-711), a Novel Glucose Cross-Link Breaker, in the Treatment of Elderly Patients With Diastolic Heart Failure. J Card Fail. 2005;11:191-5.
79. Kranstuber AL, Del Rio C, Biesiadecki BJ, Hamlin RL, Ottobre J, Gyorke S, et al. Advanced glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling. Front Physiol. 2012;3:292.
80. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
81. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96.
82. Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-91.
83. Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-89.
84. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002;109:121-30.
85. Palomer X, Capdevila-Busquets E, Botteri G, Salvadó L, Barroso E, Davidson MM, et al. PPARβ/δ attenuates palmitate-induced endoplasmic reticulum stress and induces autophagic markers in human cardiac cells. Int J Cardiol. 2014;174:110-8.
86. Alvarez-Guardia D, Palomer X, Coll T, Serrano L, Rodríguez-Calvo R, Davidson MM, et al. PPARβ/δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. Biochim Biophys Acta. 1811;2011:59-67.
87. Bedu E, Wahli W, Desvergne B. Peroxisome proliferator-activated receptor beta/delta as a therapeutic target for metabolic diseases. Expert Opin Ther Targets. 2005;9:861-73.
88. van de Weijer T, Schrauwen-Hinderling VB, Schrauwen P. Lipotoxicity in type 2 diabetic cardiomyopathy. Cardiovasc Res. 2011;92:10-8.
89. Luiken JJFP, Arumugam Y, Bell RC, Calles-Escandon J, Tandon NN, Glatz JFC, et al. Changes in fatty acid transport and transporters are related to the severity of insulin deficiency. Am J Physiol Endocrinol Metab. 2002;283:E612-21.
90. Coort SLM, Hasselbaink DM, Koonen DPY, Willems J, Coumans WA, Chabowski A, et al. Enhanced sarcolemmal FAT/CD36 content and triacylglycerol storage in cardiac myocytes from obese zucker rats. Diabetes. 2004;53:1655-63.
91. Glatz JFC, Angin Y, Steinbusch LKM, Schwenk RW, Luiken JJFP. CD36 as a target to prevent cardiac lipotoxicity and insulin resistance. Prostaglandins Leukot Essent Fatty Acids. 2013;88:71-7.
92. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010;11:155-61.
93. Ehrentraut H, Weber C, Ehrentraut S, Schwederski M, Boehm O, Knuefermann P, et al. The toll-like receptor 4-antagonist eritoran reduces murine cardiac hypertrophy. Eur J Heart Fail. 2011;13:602-10.
94. Sheedy FJ, Grebe A, Rayner KJ, Kalantari P, Ramkhelawon B, Carpenter SB, et al. CD36 coordinates NLRP3 inflammasome activation by facilitating the intracellular nucleation from soluble to particulate ligands in sterile inflammation. Nat Immunol. 2013;14:812-20.
95. Fuentes-Antras J, Loan AM, Tuñón J, Egido J, Lorenzo O. Activation of Toll-Like Receptors and Inflammasome Complexes in the Diabetic Cardiomyopathy-Associated Inflammation. Int J Endocrinol. 2014;2014:847827.
96. Pei XM, Yung BY, Yip SP, Chan LW, Wong CS, Ying M, et al. Protective effects of desacyl ghrelin on diabetic cardiomyopathy. Acta Diabetol. 2014. Sept 6.